ENXTPA:IVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Inventiva's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IVA is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: IVA's weekly volatility has decreased from 32% to 6% over the past year.


Market Performance


7 Day Return

-5.9%

IVA

6.5%

FR Biotechs

0.5%

FR Market


1 Year Return

219.6%

IVA

34.5%

FR Biotechs

-0.1%

FR Market

Return vs Industry: IVA exceeded the French Biotechs industry which returned 40.9% over the past year.

Return vs Market: IVA exceeded the French Market which returned 1% over the past year.


Shareholder returns

IVAIndustryMarket
7 Day-5.9%6.5%0.5%
30 Day-1.7%13.6%17.1%
90 Day4.8%29.8%11.8%
1 Year219.6%219.6%34.5%34.5%1.9%-0.1%
3 Year80.5%80.5%-29.5%-29.6%17.6%7.9%
5 Yearn/a-60.3%-60.5%52.7%32.0%

Long-Term Price Volatility Vs. Market

How volatile is Inventiva's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inventiva undervalued compared to its fair value and its price relative to the market?

7.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IVA is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: IVA is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IVA is overvalued based on its PB Ratio (7.8x) compared to the FR Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Inventiva forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-6.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IVA's revenue (51.5% per year) is forecast to grow faster than the French market (7.3% per year).

High Growth Revenue: IVA's revenue (51.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IVA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Inventiva performed over the past 5 years?

-32.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IVA is currently unprofitable.

Growing Profit Margin: IVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IVA is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.

Accelerating Growth: Unable to compare IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: IVA has a negative Return on Equity (-60.7%), as it is currently unprofitable.


Next Steps

Financial Health

How is Inventiva's financial position?


Financial Position Analysis

Short Term Liabilities: IVA's short term assets (€60.2M) exceed its short term liabilities (€25.2M).

Long Term Liabilities: IVA's short term assets (€60.2M) exceed its long term liabilities (€1.8M).


Debt to Equity History and Analysis

Debt Level: IVA's debt to equity ratio (24%) is considered satisfactory.

Reducing Debt: IVA's debt to equity ratio has increased from 0.9% to 24% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IVA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IVA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16% each year


Next Steps

Dividend

What is Inventiva current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IVA's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.1yrs

Average management tenure


CEO

Frédéric Cren (54 yo)

9.92yrs

Tenure

€373,583

Compensation

Mr. Frédéric Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...


CEO Compensation Analysis

Compensation vs Market: Frédéric's total compensation ($USD451.35K) is about average for companies of similar size in the French market ($USD556.39K).

Compensation vs Earnings: Frédéric's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Frédéric Cren
Co-Founder9.92yrs€373.58k14.86%
€ 61.7m
Pierre Broqua
Co-Founder9.92yrs€262.41k10.12%
€ 42.0m
Jean Volatier
Chief Financial Officer8.33yrsno datano data
Nicolas Gueugnon
Legal Directorno datano datano data
Nathalie Harroy
Head of Human Resourcesno datano datano data
Olivier Lacombe
Head of Pharmacokineticsno datano datano data
Christian Montalbetti
Head of Chemistryno datano datano data
Irena Konstantinova
Head of Biology & Pharmacologyno datano datano data
Kristina Meyer
Head of Business Developmentno datano datano data
Michael Cooreman
Chief Medical Officer0.92yrno datano data

9.1yrs

Average Tenure

56yo

Average Age

Experienced Management: IVA's management team is seasoned and experienced (9.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Frédéric Cren
Co-Founder9.92yrs€373.58k14.86%
€ 61.7m
Chris Buyse
Independent Director3.83yrs€54.00k0%
€ 0
Annick Schwebig
Independent Director3.83yrs€43.00k0%
€ 0
Jean-Louis Junien
Chairman of Scientific Advisory Boardno data€16.00kno data
Xiaoqin Lu
Independent Director2.58yrs€31.00kno data
Nawal Ouzren
Independent Director1.58yrs€20.00kno data
Heinz Maeusli
Independent Director1.58yrs€23.00kno data
Sven Francque
Member of Scientific Advisory Boardno datano datano data
Manal Abdelmalek
Member of Scientific Advisory Boardno datano datano data
Kenneth Cusi
Member of Scientific Advisory Boardno datano datano data
Glen Clack
Member of Scientific Advisory Boardno datano datano data
Hedy Kindler
Scientific Advisory Board Memberno datano datano data

3.2yrs

Average Tenure

56yo

Average Age

Experienced Board: IVA's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.6%.


Top Shareholders

Company Information

Inventiva S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inventiva S.A.
  • Ticker: IVA
  • Exchange: ENXTPA
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €415.257m
  • Shares outstanding: 38.38m
  • Website: https://www.inventivapharma.com

Number of Employees


Location

  • Inventiva S.A.
  • 50 rue de Dijon
  • Daix
  • Burgundy
  • 21121
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IVAENXTPA (Euronext Paris)YesOrdinary SharesFREURFeb 2017
0RNKLSE (London Stock Exchange)YesOrdinary SharesGBEURFeb 2017
IVEV.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2017
6IVDB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2017
IVAPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURFeb 2017
6IVADB (Deutsche Boerse AG)ADSDEEURJul 2020
IVANasdaqGM (Nasdaq Global Market)ADSUSUSDJul 2020

Biography

Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to tre...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 19:16
End of Day Share Price2020/12/02 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.